SL PHARM released its performance for the first half of the year, with a net profit attributable to the parent company of 121 million yuan, an increase of 309.08%
I'm LongbridgeAI, I can summarize articles.
According to the Zhitong Finance APP, SL PHARM released its semi-annual report for 2025, showing an operating income of 305 million yuan, a year-on-year decrease of 22.24%. The net profit attributable to shareholders of the listed company was 121 million yuan, a year-on-year increase of 309.08%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 26.044 million yuan, a year-on-year decrease of 78.42%. The basic earnings per share were 0.12 yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments